EP4226916A1 — Lipid nanoparticle comprising phosphatidylserine
Assigned to Universitaet Basel · Expires 2023-08-16 · 3y expired
What this patent protects
The invention relates to a lipid nanoparticle (LNP) comprising at least one cationic matrix-forming lipid and 0.5 mol% to 10 mol% phosphatidylserine, helper lipids and/or therapeutic agents such as proteins, negatively charged nanoparticles, nucleic acids. The invention further r…
USPTO Abstract
The invention relates to a lipid nanoparticle (LNP) comprising at least one cationic matrix-forming lipid and 0.5 mol% to 10 mol% phosphatidylserine, helper lipids and/or therapeutic agents such as proteins, negatively charged nanoparticles, nucleic acids. The invention further relates to a vector, pharmaceutical composition and/or needle-free injection device comprising the LNP of the invention. The invention also provides methods for production of the LNP and vector of the invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.